SAMDI Tech is acquired by Charles River Laboratories By CIOTechOutlook Team

SAMDI Tech is acquired by Charles River Laboratories

CIOTechOutlook Team | Tuesday, 31 January 2023, 04:18 IST

  •  No Image
SAMDI Tech, Inc., a top supplier of high-quality, label-free high-throughput screening (HTS) solutions for drug discovery research, was acquired by Charles River Laboratories International, Inc. The relationship between the companies, which started in 2018, has now come to an end with the acquisition.
 
SAMDI Tech, a Chicago, Illinois-based company, provides a proprietary mass spectrometry (MS) technology for the identification of binding interactions and high-throughput study of biological activities. With this method, false positive results are minimised, reagent usage is decreased, and multiplexing is possible without limiting the test settings.
 
Clients are favouring these solutions more frequently in order to shorten the timeframe and lower the cost of finding a lead drug candidate, promote more productive research and high-quality scientific data, help clients make important go-or-no-go decisions earlier, and advance their projects more quickly. Additionally, optical and radioactivity capabilities, cell-based assays, and an internal stockpile of more than 500,000 drug-like small compounds are all included in SAMDI Tech's comprehensive drug discovery solutions.
 
By measuring biochemical activities and identifying binding interactions for almost any small molecule drug target, the end-to-end portfolio, industry-leading scientific expertise, and cutting-edge MS technology of SAMDI Tech have the potential to significantly accelerate and augment clients' discovery efforts.
 
The acquisition will build a comprehensive, industry-leading library of drug discovery solutions and give Charles River's clients effortless access to the best label-free HTS MS platform.
 
The acquisition of SAMDI Tech's state-of-the-art high-throughput screening technology, according to James C. Foster, chairman, president, and chief executive officer of Charles River Laboratories, "further strengthens Charles River's drug discovery capabilities and enhances our unique ability to serve as an integrated partner to support our clients' early-stage research."
 
SAMDI Tech’s platform combined with our premier, end-to-end drug discovery portfolio will generate better data and faster hit identification and is another step to accelerate our clients’ drug discovery efforts. With over a decade of industry experience and the successful, existing partnership, we believe the addition of SAMDI Tech will continue to generate new business opportunities and we are pleased to welcome them to the Charles River family."

CIO Viewpoint

Product Adoption: Realizing The Real Value

By Ashish Pandey, CIO, GSK Consumer Healthcare India

CXO Insights

HIT Promotional Products: Fostering Empowerment...

By Eric Shonebarger, President & Lori Thibado, Director of Order Entry & Art

Elevating Patient Experience with Remote...

By Vineet Aggarwal, CIO, Paras Healthcare

Facebook